Evidera

Evidera

Evidera operates as a business unit inside PPD, the contract research organization that Thermo Fisher Scientific acquired for $17.4B in 2021. The unit provides real-world evidence (RWE) consulting and research services to the pharmaceutical and biotech industry. Its offerings span observational studies, pregnancy and lactation studies, patient-centered research, and implementation science — all built to support drug approval and market access across the product life cycle. Evidera's team designs and executes non-interventional studies using both primary data collection and proprietary secondary data sources, including the PPD CorEvitas Registries — independent longitudinal registries that capture clinician- and patient-reported information. Work spans therapeutic areas and geographies, with clients including top global drugmakers. The unit markets to stakeholders in North America, Europe, and Asia. Services include clinical trial feasibility support, endpoint optimization, comparative effectiveness research, safety monitoring, and value-based pricing evidence. The group employs a multidisciplinary global team of scientists, epidemiologists, and data analysts. Its service model is fee-for-service project work for pharmaceutical sponsors. No public information exists on revenue, AUM, total employees, or named principals. Evidera does not operate as an investment vehicle and does not deploy capital; the firm is a service provider within its parent's broader clinical research segment. Evidera's structural differentiator is its integration into the largest standalone CRO — PPD — which gives it access to a global clinical trial infrastructure and proprietary data assets like CorEvitas Registries. This positions Evidera as an internal RWE capability rather than a standalone consultancy, allowing it to deliver evidence packages that span from pre-approval through post-market commitments.